Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 3/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13769500 | 0.90 | MAPK14 (0.48) | MAPK14BRD4RAD52ALDH1A1SMN1; SMN2 | |
| SCHEMBL14440847 | 0.89 | MAPK14 (0.46) | MAPK14BRD4RAD52ALDH1A1SMN1; SMN2 | |
| SCHEMBL4014863 | 0.87 | TGFBR1 (0.40) | MAPK14MAPK8 | |
| SCHEMBL4018754 | 0.86 | CTSA (0.36) | MAPK14MAPK8DGAT2 | |
| SCHEMBL4016504 | 0.85 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL4017429 | 0.85 | SCN9A (0.39) | MAPK14ALDH1A1SMN1; SMN2 | |
| SCHEMBL4015352 | 0.80 | TRPA1 (0.41) | MAPK14 | |
| SCHEMBL4019146 | 0.79 | TRPA1 (0.41) | MAPK14SMN1; SMN2 | |
| SCHEMBL4015456 | 0.79 | MAPK14 (0.41) | MAPK14BRD4MAPK8MAPK10ALDH1A1 | |
| SCHEMBL5097216 | 0.79 | MAPK14 (0.42) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | claimed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | MAPK14 33/4885BRD4 1593/4885RAD52 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.